The PurpleLab®

Healthcare Analytics

Articles

This research, led by Grace K. Kane, Douglas Londono, and Nathan J. Markward, explores how the timing of biomarker testing affects survival outcomes in patients with non-small cell lung cancer (NSCLC). Using real-world claims data, it identifies disparities in testing and treatment patterns and their impact on mortality rates.   Biomarker testing is essential to…

Videos

Price transparency mandates have introduced an unprecedented volume of data — but turning that data into actionable strategy remains a challenge. Health systems and payers alike are still navigating how to translate pricing insights into stronger contract terms, smarter network expansion and more aligned pricing strategies.

Videos

Using non-small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage RWD to eliminate blind spots in the patient journey.

Articles

At ISPOR 2025 in Montreal, PurpleLab presented a research poster titled “Trends in Attainment of the Kidney Health Evaluation for Patients with Diabetes Measure among Insured Individuals in the US, 2021-2024”. The study, conducted by Stephan Dunning, MBA, MS, Douglas Londono, PhD, Yeison Ortiz, BS, Anna Wang, PhD, Nathan Markward, PhD, MPH, and Steven Emrick, BS,…

Articles

At ISPOR 2025 in Montreal, PurpleLab presented a research poster titled “Intersectional Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy (MAIHDA) for Social Determinants of Health and Pregnancy Outcomes.” The study, conducted by Anna Wang, PhD, Francis Concannon, BS, Daria Eremina, PhD, and Douglas Londono, PhD, applied MAIHDA to analyze how overlapping social factors influence…

Articles

Real-World Data: The Cornerstone of Life Science Consulting Life sciences are at an inflection point. As pressure mounts to develop therapies faster, prove real-world value to payers, and personalize interventions, traditional data sources are hitting their limits. Real-world data (RWD), particularly claims data, has emerged as a critical lever across the product lifecycle. For consultancies,…

Articles

Why Real-World Evidence Matters Beyond Clinical Trials Market access has never been more complex than it is right now. In a world where payers are tightening the purse strings and every therapeutic area feels like a battleground, just getting a therapy onto formulary, or getting a diagnostic test approved isn’t enough. You need to prove…

Articles

The Old Operating System Is Crashing Let’s be honest: pharma’s old operating system is starting to show its age. The traditional model – built around blockbuster drugs, top-down messaging and rigid pipelines – is crashing under the weight of modern complexity. Shareholder returns are sluggish. CEOs are second-guessing legacy bets. The pressure to demonstrate real…

Articles

Gram-negative bacteria. The very name can send shivers down the spines of healthcare professionals. These microorganisms, characterized by their complex cell wall structure, are increasingly developing resistance to even our strongest antibiotics.  If bacterial infections in general are a concern, gram-negative bacteria are particularly challenging – since even minor infections can become life-threatening when they…